Acurx Pharmaceuticals (ACXP) Competitors $0.38 0.00 (-0.63%) Closing price 04:00 PM EasternExtended Trading$0.38 0.00 (0.00%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACXP vs. ALLK, ALXO, HOWL, BRNS, CVKD, FGEN, IRD, GDTC, DARE, and GBIOShould you be buying Acurx Pharmaceuticals stock or one of its competitors? The main competitors of Acurx Pharmaceuticals include Allakos (ALLK), ALX Oncology (ALXO), Werewolf Therapeutics (HOWL), Barinthus Biotherapeutics (BRNS), Cadrenal Therapeutics (CVKD), FibroGen (FGEN), Opus Genetics (IRD), CytoMed Therapeutics (GDTC), Daré Bioscience (DARE), and Generation Bio (GBIO). These companies are all part of the "pharmaceutical products" industry. Acurx Pharmaceuticals vs. Allakos ALX Oncology Werewolf Therapeutics Barinthus Biotherapeutics Cadrenal Therapeutics FibroGen Opus Genetics CytoMed Therapeutics Daré Bioscience Generation Bio Acurx Pharmaceuticals (NASDAQ:ACXP) and Allakos (NASDAQ:ALLK) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, community ranking, profitability, risk, valuation, institutional ownership and dividends. Does the media refer more to ACXP or ALLK? In the previous week, Acurx Pharmaceuticals and Acurx Pharmaceuticals both had 1 articles in the media. Allakos' average media sentiment score of 1.87 beat Acurx Pharmaceuticals' score of 1.44 indicating that Allakos is being referred to more favorably in the news media. Company Overall Sentiment Acurx Pharmaceuticals Positive Allakos Very Positive Is ACXP or ALLK more profitable? Allakos' return on equity of -140.87% beat Acurx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Acurx PharmaceuticalsN/A -392.36% -223.78% Allakos N/A -140.87%-86.22% Do analysts rate ACXP or ALLK? Acurx Pharmaceuticals currently has a consensus target price of $12.00, indicating a potential upside of 3,057.89%. Allakos has a consensus target price of $2.00, indicating a potential upside of 519.20%. Given Acurx Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Acurx Pharmaceuticals is more favorable than Allakos.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acurx Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Allakos 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20 Does the MarketBeat Community favor ACXP or ALLK? Allakos received 167 more outperform votes than Acurx Pharmaceuticals when rated by MarketBeat users. However, 94.12% of users gave Acurx Pharmaceuticals an outperform vote while only 58.84% of users gave Allakos an outperform vote. CompanyUnderperformOutperformAcurx PharmaceuticalsOutperform Votes1694.12% Underperform Votes15.88%AllakosOutperform Votes18358.84% Underperform Votes12841.16% Which has stronger earnings & valuation, ACXP or ALLK? Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Allakos, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAcurx PharmaceuticalsN/AN/A-$14.58M-$0.87-0.44AllakosN/AN/A-$185.70M-$1.32-0.24 Which has more volatility & risk, ACXP or ALLK? Acurx Pharmaceuticals has a beta of -1.36, suggesting that its stock price is 236% less volatile than the S&P 500. Comparatively, Allakos has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500. Do institutionals & insiders hold more shares of ACXP or ALLK? 11.5% of Acurx Pharmaceuticals shares are owned by institutional investors. Comparatively, 84.6% of Allakos shares are owned by institutional investors. 29.6% of Acurx Pharmaceuticals shares are owned by company insiders. Comparatively, 16.1% of Allakos shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryAllakos beats Acurx Pharmaceuticals on 7 of the 13 factors compared between the two stocks. Remove Ads Get Acurx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ACXP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACXP vs. The Competition Export to ExcelMetricAcurx PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.51M$6.32B$5.33B$7.57BDividend YieldN/A3.23%5.11%4.32%P/E Ratio-0.356.7921.7317.81Price / SalesN/A225.96379.2094.61Price / CashN/A65.6738.1534.64Price / Book1.125.866.464.00Net Income-$14.58M$141.86M$3.20B$247.23M7 Day Performance24.59%8.98%6.54%7.26%1 Month Performance-17.57%-12.65%-8.55%-6.26%1 Year Performance-76.76%-11.99%10.33%-0.18% Acurx Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACXPAcurx Pharmaceuticals2.2672 of 5 stars$0.38-0.6%$12.00+3,057.9%-78.4%$8.51MN/A-0.353ALLKAllakos4.4785 of 5 stars$0.32+1.4%$2.00+526.0%-71.1%$28.82MN/A-0.16190Positive NewsALXOALX Oncology3.3417 of 5 stars$0.54+3.8%$4.14+673.4%-96.2%$28.58MN/A-0.1840Gap UpHOWLWerewolf Therapeutics2.4939 of 5 stars$0.63-9.8%$9.00+1,328.6%-83.5%$28.24M$1.89M-0.4140Gap UpBRNSBarinthus Biotherapeutics3.0139 of 5 stars$0.69+1.8%$5.17+644.5%-77.7%$28.00M$14.97M-0.47107Short Interest ↓Positive NewsCVKDCadrenal Therapeutics2.6821 of 5 stars$14.68-9.2%$32.00+118.0%N/A$27.60MN/A-2.204Gap DownFGENFibroGen4.4853 of 5 stars$0.27-2.5%$10.00+3,561.7%-76.9%$27.56M$29.62M-0.22570Analyst ForecastPositive NewsIRDOpus Genetics1.9632 of 5 stars$0.85-4.5%$8.00+845.6%N/A$27.11M$10.99M-0.7814Gap UpGDTCCytoMed Therapeutics2.4336 of 5 stars$2.35-1.5%$5.00+113.2%+15.7%$25.65MN/A0.00N/AGap DownDAREDaré Bioscience2.1423 of 5 stars$2.88-0.3%$24.00+733.3%-48.0%$25.49M$9,784.00-4.8830Short Interest ↓GBIOGeneration Bio3.2203 of 5 stars$0.38+0.8%$7.33+1,853.5%-89.9%$25.16M$19.89M-0.17150 Remove Ads Related Companies and Tools Related Companies Allakos Alternatives ALX Oncology Alternatives Werewolf Therapeutics Alternatives Barinthus Biotherapeutics Alternatives Cadrenal Therapeutics Alternatives FibroGen Alternatives Opus Genetics Alternatives CytoMed Therapeutics Alternatives Daré Bioscience Alternatives Generation Bio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACXP) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acurx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acurx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
